Russia cancer vaccine enteromix: Russia’s Federal Medical and Biological Agency (FMBA) has announced an mRNA-based cancer vaccine, Enteromix, that it says is ready for clinical use.
FMBA chief Veronika Skvortsova disclosed the development at the Eastern Economic Forum, according to state media reports. The platform uses messenger RNA to instruct cells to produce proteins that trigger an immune response against tumour cells, a similar approach to some COVID-19 vaccines.
Also Read | US halts mRNA vaccine funding; scientists call it ‘dangerous’
Skvortsova said Enteromix has been studied for many years, including three years of necessary preclinical testing, which showed that the vaccine is safe for repeated use and has strong effects against tumours. Depending on cancer type, preclinical models recorded tumour shrinkage or slower growth in the range of 60–80%, alongside improved survival in test subjects.
The first clinical focus is colorectal cancer, with programmes also advancing for glioblastoma and certain melanomas, including ocular melanoma. Separately, Russian media have reported initial human testing involving 48 volunteers at national research centres, describing high efficacy and no serious adverse events, and characterising the programme as close to regulatory review by the Health Ministry.
FMBA officials said Enteromix differs from conventional cancer vaccines, which often take a one-size-fits-many approach and have historically underperformed, in two ways. Each dose is fully personalised to the genetic profile of an individual patient’s tumour to improve target specificity and immune engagement. And the mRNA platform is designed for rapid development and scalability, enabling faster adaptation to different cancers compared with older vaccine technologies.
The announcement was made during the 10th Eastern Economic Forum in Vladivostok, which drew international participants. Further details on trial design, endpoints and peer-reviewed data have not yet been released.
